



Marksans Pharma Ltd.

The Bombay Stock Exchange Limited
Corporate Relation Department
Phiroze Jeejeebhoi Towers,
Dalal Street,
Mumbai 400 001

The National Stock Exchange of India Ltd
Listing Department,
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (E), Mumbai- 400 051

2nd May, 2016

PRESS RELEASE

Marksans Pharma Limited announces USFDA approval for Metformin Hydrochloride Extended-Release (ER) Tablets USP 500mg and 750mg (ANDA 090295)

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride Extended-Release (ER) Tablets USP 500 mg and 750 mg.

Metformin Hydrochloride ER Tablets USP 500mg and 750mg is therapeutically equivalent to the reference listed drug Glucophage XR Extended-release Tablets 500mg and 750mg respectively of Bristol Myers Squibb (BMS).

Metformin Hydrochloride ER Tablets are oral anti-hyperglycemic drugs indicated as an adjunct to diet and exercise to improve glycemic control in patients with type-2 diabetes. The Annual sale of the product is approximately US\$ 230 millions.

This product approval endorses the capability of Marksans to develop and deliver products on a high barrier platform technology of extended release tablets. Extended release is an advanced technology and is a solution to patient compliance to avoid repeated dosages at short intervals.

Thanking you

Yours faithfully,
For Marksans Pharma Limited

For *DD. Pandiwala*

Harshavardhan Panigrahi
Company Secretary & Manager-Legal

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com